(VIANEWS) – Shares of BERGENBIO (Oslo Børs Benchmark Index_GI: BGBIO.OL) fell by a staggering 31.35% in 21 sessions from kr7.24 to kr4.97 at 13:26 EST on Wednesday, following the last session’s upward trend. Oslo Børs Benchmark Index_GI is sliding 0.11% to kr1,175.21, after two successive sessions in a row of gains.
About BERGENBIO
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.
Earnings Per Share
As for profitability, BERGENBIO has a trailing twelve months EPS of kr-3.431.
More news about BERGENBIO (BGBIO.OL).
